|
[1]
|
NCD Risk Factor Collaboration (NCD-RisC) (2024) Worldwide Trends in Diabetes Prevalence and Treatment from 1990 to 2022: A Pooled Analysis of 1108 Population-Representative Studies with 141 Million Participants. The Lancet, 404, 2077-2093. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Gwira, J.A., Fryar, C.D. and Gu, Q. (2024) Prevalence of Total, Diagnosed, and Undiagnosed Diabetes in Adults: United States, August 2021-August 2023. NCHS Data Brief.
|
|
[3]
|
Jia, W., Chan, J.C., Wong, T.Y. and Fisher, E.B. (2025) Diabetes in China: Epidemiology, Pathophysiology and Multi-omics. Nature Metabolism, 7, 16-34. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Laakso, M. (2001) Cardiovascular Disease in Type 2 Diabetes: Challenge for Treatment and Prevention. Journal of Internal Medicine, 249, 225-235. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L.R. and Sowers, J. (2019) Diabetes and Cardiovascular Disease: An Update. Current Diabetes Reports, 19, Article No. 161. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Ji, L., Hu, D., Pan, C., Weng, J., Huo, Y., Ma, C., et al. (2013) Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients. The American Journal of Medicine, 126, 925.e11-925.e22. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Wang, L., Li, X., Wang, Z., Bancks, M.P., Carnethon, M.R., Greenland, P., et al. (2021) Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes among US Adults, 1999-2018. JAMA, 326, Article 704. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Gandotra, P. and Miller, M. (2008) The Role of Triglycerides in Cardiovascular Risk. Current Cardiology Reports, 10, 505-511. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., et al. (2007) Triglycerides and the Risk of Coronary Heart Disease. Circulation, 115, 450-458. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 血脂相关性心血管剩留风险控制的中国专家共识[J]. 中华心血管病杂志, 2012, 40(7): 547-553.
|
|
[11]
|
赵水平, 张大庆, 赵旺. 中国血脂学[M]. 岳阳: 湖南科学技术出版社, 2019.
|
|
[12]
|
Ginsberg, H.N., Packard, C.J., Chapman, M.J., Borén, J., Aguilar-Salinas, C.A., Averna, M., et al. (2021) Triglyceride-rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies—A Consensus Statement from the European Atherosclerosis Society. European Heart Journal, 42, 4791-4806. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Chirieac, D.V., Chirieac, L.R., Corsetti, J.P., Cianci, J., Sparks, C.E. and Sparks, J.D. (2000) Glucose-Stimulated Insulin Secretion Suppresses Hepatic Triglyceride-Rich Lipoprotein and Apob Production. American Journal of Physiology-Endocrinology and Metabolism, 279, E1003-E1011. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Young, S.G. and Zechner, R. (2013) Biochemistry and Pathophysiology of Intravascular and Intracellular Lipolysis. Genes & Development, 27, 459-484. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Dijk, W., Rimbert, A., Sotin, T., Le May, C. and Cariou, B. (2026) Versatile Functions of Hepatic Lipase in Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 46, 105-118. [Google Scholar] [CrossRef]
|
|
[16]
|
Fried, S.K., Russell, C.D., Grauso, N.L. and Brolin, R.E. (1993) Lipoprotein Lipase Regulation by Insulin and Glucocorticoid in Subcutaneous and Omental Adipose Tissues of Obese Women and Men. Journal of Clinical Investigation, 92, 2191-2198. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Gu, C., Wang, N., Ren, P., Wu, X., Pang, B., Zhang, S., et al. (2021) Association between Postprandial Lipoprotein Subclasses and Framingham Cardiovascular Disease Risk Stratification. Clinical Biochemistry, 89, 51-57. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
张晶梅, 彭红兵, 李国锋, 等. 基于VAP技术检测脂蛋白残粒和低密度脂蛋白颗粒浓度对颈动脉斑块的诊断价值[J]. 中华检验医学杂志, 2022, 45(7): 704-710.
|
|
[20]
|
Huh, J.H., Han, K., Cho, Y.K., Roh, E., Kang, J.G., Lee, S.J., et al. (2022) Remnant Cholesterol and the Risk of Cardiovascular Disease in Type 2 Diabetes: A Nationwide Longitudinal Cohort Study. Cardiovascular Diabetology, 21, Article No. 228. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., et al. (2018) Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Journal of Atherosclerosis and Thrombosis, 25, 846-984. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Lai, C., Gervis, J.E., Parnell, L.D., Lichtenstein, A.H. and Ordovas, J.M. (2025) Changes in Triglyceride-Rich Lipoprotein Particle Profiles in Response to One-Week on a Low Fat or Mediterranean Diet by TCF7L2 Rs7903146 Genotype: A Randomized Crossover Dietary Intervention Trial. Genes & Nutrition, 20, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Malick, W.A., Waksman, O., Do, R., Koenig, W., Pradhan, A.D., Stroes, E.S.G., et al. (2023) Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies. Journal of the American College of Cardiology, 81, 1646-1658. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Kosmas, C.E., Rallidis, L.S., Hoursalas, I., Papakonstantinou, E.J. and Kostara, C.E. (2026) Angiopoietin-Like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. International Journal of Molecular Sciences, 27, Article 921. [Google Scholar] [CrossRef]
|
|
[25]
|
de Moura de Souza, M., Mendes, B.X., Defante, M.L.R., de Athayde de Hollanda Morais, B.A., Martins, O.C., Prizão, V.M., et al. (2025) Apolipoprotein C-III Inhibitors for the Treatment of Hypertriglyceridemia: A Meta-Analysis of Randomized Controlled Trials. Metabolism, 167, Article 156187. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Ivanova, E.A., Myasoedova, V.A., Melnichenko, A.A., Grechko, A.V. and Orekhov, A.N. (2017) Small Dense Low‐density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 1273042. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Ebenbichler, C.F., Laimer, M., Kaser, S., Ritsch, A., Sandhofer, A., Weiss, H., et al. (2002) Relationship between Cholesteryl Ester Transfer Protein and Atherogenic Lipoprotein Profile in Morbidly Obese Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1465-1469. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Puig-Jové, C., Castelblanco, E., Falguera, M., Hernández, M., Soldevila, B., Julián, M.T., et al. (2022) Advanced Lipoprotein Profile in Individuals with Normal and Impaired Glucose Metabolism. Revista Española de Cardiología (English Edition), 75, 22-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. a Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Bourgonje, A.R., Connelly, M.A., van Goor, H., van Dijk, P.R. and Dullaart, R.P.F. (2023) Both LDL and HDL Particle Concentrations Associate Positively with an Increased Risk of Developing Microvascular Complications in Patients with Type 2 Diabetes: Lost Protection by HDL (Zodiac-63). Cardiovascular Diabetology, 22, Article No. 169. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Otvos, J.D., Collins, D., Freedman, D.S., Shalaurova, I., Schaefer, E.J., McNamara, J.R., et al. (2006) Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 113, 1556-1563. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., et al. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clinical Lipidology, 9, 129-169. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Garber, A.J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M.J., Barzilay, J.I., et al. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2020 Executive Summary. Endocrine Practice, 26, 107-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
王娟, 刘志云, 丁宏胜, 等. 冠状动脉粥样硬化性心脏病患者小而密低密度脂蛋白、脂蛋白相关磷脂酶A2和组织蛋白酶S水平与颈动脉粥样硬化的相关性[J]. 中华高血压杂志, 2020, 28(6): 572-575.
|
|
[35]
|
Drexel, H., Larcher, B., Mader, A., Vonbank, A., Heinzle, C.F., Moser, B., et al. (2021) The LDL-C/ApoB Ratio Predicts Major Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease. Atherosclerosis, 329, 44-49. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kokubo, Y., Watanabe, M., Higashiyama, A. and Honda-Kohmo, K. (2020) Small-Dense Low-Density Lipoprotein Cholesterol: A Subclinical Marker for the Primary Prevention of Coronary Heart Disease. Journal of Atherosclerosis and Thrombosis, 27, 641-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Ikezaki, H., Lim, E., Cupples, L.A., Liu, C., Asztalos, B.F. and Schaefer, E.J. (2021) Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. Journal of the American Heart Association, 10, e019140. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
陆静芬, 赵金燕, 陈旭, 等. 小而密低密度脂蛋白胆固醇和HbA 1C对年龄≥ 65岁2型糖尿病患者心脑血管事件发生的预测价值[J]. 中华检验医学杂志, 2020, 43(3): 250-254.
|
|
[39]
|
Duran, E.K., Aday, A.W., Cook, N.R., Buring, J.E., Ridker, P.M. and Pradhan, A.D. (2020) Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 75, 2122-2135. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Ma, X., Wang, Q., Hu, X., Wang, X., Zhao, Y., Liu, X., et al. (2024) Association of sdLDL-C with Incident Carotid Plaques with Stable and Vulnerable Morphology: A Prospective Cohort Study. Stroke, 55, 576-585. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association, 285, 2486-2497. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., et al. (2023) Prospective Randomized Comparative Study of the Effect of Pemafibrate Add‐On or Double Statin Dose on Small Dense Low‐Density Lipoprotein‐cholesterol in Patients with Type 2 Diabetes and Hypertriglyceridemia on Statin Therapy. Journal of Diabetes Investigation, 14, 1401-1411. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Mahmood, T., Miles, J.R., Minnier, J., Tavori, H., DeBarber, A.E., Fazio, S., et al. (2024) Effect of PCSK9 Inhibition on Plasma Levels of Small Dense Low Density Lipoprotein-Cholesterol and 7-Ketocholesterol. Journal of Clinical Lipidology, 18, e50-e58. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Tall, A.R. and Small, D.M. (1978) Plasma High-Density Lipoproteins. New England Journal of Medicine, 299, 1232-1236. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Zhang, X. and van der Vorst, E.P.C. (2024) High-Density Lipoprotein Modifications: Causes and Functional Consequences in Type 2 Diabetes Mellitus. Cells, 13, Article 1113. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Denimal, D. (2023) Antioxidant and Anti-Inflammatory Functions of High-Density Lipoprotein in Type 1 and Type 2 Diabetes. Antioxidants, 13, Article 57. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Hayek, T., Azrolan, N., Verdery, R.B., Walsh, A., Chajek-Shaul, T., Agellon, L.B., et al. (1993) Hypertriglyceridemia and Cholesteryl Ester Transfer Protein Interact to Dramatically Alter High Density Lipoprotein Levels, Particle Sizes, and Metabolism. Studies in Transgenic Mice. Journal of Clinical Investigation, 92, 1143-1152. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Ruotolo, G., Parlavecchia, M., Taskinen, M., Galimberti, G., Zoppo, A., Le, N., et al. (1994) Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of Increased Hepatic Lipase Activity. Diabetes Care, 17, 6-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Goldberg, I.J. (2001) Diabetic Dyslipidemia: Causes and Consequences. The Journal of Clinical Endocrinology & Metabolism, 86, 965-971. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
U.K. Prospective Diabetes Study 27 (1997) U.K. Prospective Diabetes Study 27: Plasma Lipids and Lipoproteins at Diagnosis of NIDDM by Age and Sex. Diabetes Care, 20, 1683-1687. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
White, J., Swerdlow, D.I., Preiss, D., Fairhurst-Hunter, Z., Keating, B.J., Asselbergs, F.W., et al. (2016) Association of Lipid Fractions with Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology, 1, 692-699. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Fall, T., Xie, W., Poon, W., Yaghootkar, H., Mägi, R., Knowles, J.W., et al. (2015) Using Genetic Variants to Assess the Relationship between Circulating Lipids and Type 2 Diabetes. Diabetes, 64, 2676-2684. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
AIM-HIGH Investigators (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine, 365, 2255-2267. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
HPS2-THRIVE Collaborative Group (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 371, 203-212. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Barter, P.J., Rye, K., Tardif, J., Waters, D.D., Boekholdt, S.M., Breazna, A., et al. (2011) Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin a 1c in Subjects in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation, 124, 555-562. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K. and van der Vorst, E.P.C. (2020) Interaction between High-Density Lipoproteins and Inflammation: Function Matters More than Concentration! Advanced Drug Delivery Reviews, 159, 94-119. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Lui, D.T.W., Cheung, C., Lee, A.C.H., Wong, Y., Shiu, S.W.M. and Tan, K.C.B. (2021) Carbamylated HDL and Mortality Outcomes in Type 2 Diabetes. Diabetes Care, 44, 804-809. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Schalkwijk, C.G. and Stehouwer, C.D.A. (2020) Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases. Physiological Reviews, 100, 407-461. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Márquez, A.B., Nazir, S. and van der Vorst, E.P.C. (2020) High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? Biomedicines, 8, 549. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
von Eckardstein, A., Nordestgaard, B.G., Remaley, A.T. and Catapano, A.L. (2022) High-Density Lipoprotein Revisited: Biological Functions and Clinical Relevance. European Heart Journal, 44, 1394-1407. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Soria-Florido, M.T., Schröder, H., Grau, M., Fitó, M. and Lassale, C. (2020) High Density Lipoprotein Functionality and Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis. Atherosclerosis, 302, 36-42. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Mahrooz, A. (2026) Insights to HDL Dysfunctionality: Hypothesis of Exhausted HDL. Diabetes Research and Clinical Practice, 233, Article 113145. [Google Scholar] [CrossRef]
|
|
[63]
|
Marcovina, S.M. (2023) Lipoprotein(a): A Genetically Determined Risk Factor for Cardiovascular Disease. Critical Reviews in Clinical Laboratory Sciences, 60, 560-572. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Clarke, R., Peden, J.F., Hopewell, J.C., Kyriakou, T., Goel, A., Heath, S.C., et al. (2009) Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. New England Journal of Medicine, 361, 2518-2528. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
中华医学会检验医学分会, 中国医师协会检验医师分会, 中国生物化学与分子生物学会脂质与脂蛋白专业委员会, 等. 中国临床血脂检测指南[J]. 中华检验医学杂志, 2022, 45(10): 1017-1033.
|
|
[66]
|
北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|
|
[67]
|
Mach, F., Koskinas, K.C., Roeters van Lennep, J.E., Tokgözoğlu, L., Badimon, L., Baigent, C., et al. (2025) 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 46, 4359-4378. [Google Scholar] [CrossRef]
|
|
[68]
|
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D.C., Mauro, M.S., Raffo, C., et al. (2025) Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation, 151, 400-415. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Sosnowska, B., Surma, S. and Banach, M. (2022) Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals, 15, Article 1573. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Begue, F., Apalama, M.L., Lambert, G. and Meilhac, O. (2023) HDL as a Treatment Target: Should We Abandon This Idea? Current Atherosclerosis Reports, 25, 1093-1099. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J., Baum, S.J., Steinhagen-Thiessen, E., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 382, 244-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
O’Donoghue, M.L., Rosenson, R.S., Gencer, B., López, J.A.G., Lepor, N.E., Baum, S.J., et al. (2022) Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England Journal of Medicine, 387, 1855-1864. [Google Scholar] [CrossRef] [PubMed]
|